2025-06-12-花旗集团-薛定谔公司（SDGR）_薛定谔公司（SDGR.O）_SGR_-_1505有效_耐受性良好但疗效情况不完整；管理层接下来将寻求联合治疗方案_13页_645kb

Schrödinger Inc (SDGR.O) Flash Analysis Summary

Clinical Developments

• Pipeline Update: SGR-1505 (MALT1 inhibitor) showed an overall response rate (ORR) of 22% in a Phase 1 study for Waldenström macroglobulinemia, with all treated patients responding.
• Next Steps: Management plans to escalate doses in Phase 1 and study the drug in more aggressive tumor types like DLBCL. Initial focus will be on combination therapies (e.g., with BTKi/BCL2i for Phase 2).
• Investor Caution: Despite progress, efficacy data is still needed for pursuing partnerships, keeping investor enthusiasm cautious.

Financial/Equity Rating

• Citi Take: Buy rating with High Risk assessment.
• Price Analysis: Target price is set at $39.00, reflecting a 46.1% expected total return.
• Valuation Methodology: Based on a sum-of-the-parts analysis:
  • Software Business: 4.5x EV/revenue.
  • Drug Discovery Business: NPV analysis with a 12.5% discount rate.

Risks

• Atypical Business Model: Shares exhibit volatility typical of both software and biotech firms.
• Software Revenue: Top-line performance of the software division impacts overall stock stability.
• Pipeline Risk: Delays or negative updates in clinical results could lead to share price depreciation.
• Volatility and Capital Needs: High stock volatility and capital-intensive drug development may necessitate dilutive financing.

Valuation & Target Price

• Key Metrics:
  • Target price: US$39.00 (current price: US$26.69).
  • Expected dividend yield: 0.0%.
  • Expected share price return: 46.1%.

Analyst Notes

• Proceed with caution due to high risk and speculative drug development outcomes.
• Short-term investor enthusiasm is limited due to ongoing trials and need for efficacy confirmation.